Disease Markers

Disease Markers / 2009 / Article

Open Access

Volume 27 |Article ID 617863 | 6 pages | https://doi.org/10.3233/DMA-2009-0667

Apolipoprotein E Genotypes in Mexican Patients with Parkinson's Disease

Received18 Dec 2009
Accepted18 Dec 2009

Abstract

Background: The association of the apolipoprotein (Apo E) -epsilon4 allele to neurodegenerative diseases such as Parkinson’s disease (PD) has been analyzed in several studies. This association has been identified by amyloid deposits and neurofibrillary tangles in the brains of patients with neurodegenerative diseases.Method: In this study the possible relationship between Apo E alleles and PD patients was analyzed in 105 patients with PD and 107 healthy controls from a Mexican population.Results: Allele analysis in PD vs. controls was: ε2 in 6% and 2.3%, respectively; ε3 in 73% and 88.3%; and ε4 in 21% and 9.4%. The ε3 allele showed a protective risk effect with an Odds ratio (OR) of 0.36 (95%CI 0.20-0.61) and p < 0.05; contrary results were observed for the ε4 allele, which showed an increased risk for PD, with an OR of 2.57(95% CI 1.42-4.79) and p < 0.05. Upon multivariate analysis showed PD risk was evident in patients who were carriers of the genotype ε34; age group (fifty or more years) and had exposure to pesticides and solvents (p < 0.05).Conclusions: The ε33; ε34 genotypes of the Apo E, were positively associated with sporadic PD.

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

384 Views | 375 Downloads | 5 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.